top of page

Evren Announces NIH Notice of Intent to Fund the Phoenix® Laboratory Phase I SBIR

Updated: Dec 23, 2020

Gainesville, FL – November 18, 2020 – We are pleased to announce that on November 18, 2020, the National Institute of Mental Health sent us a Notice of Intent to Fund our Phase I SBIR application for development of the Phoenix® Laboratory, a portable, programmable device which will empower researchers here and abroad to explore various modes of transcutaneous vagal nerve stimulation (tVNS). The Phoenix® Laboratory is in an easy to use, take-home device that supports both home and clinic-based research targeting the auricular branch of the vagus nerve.

Neil Euliano, Ph.D., Evren’s Chief Technical Officer and the Principal Investigator on the Grant, said, “Transcutaneous Vagus Nerve Stimulation shows significant promise in reducing symptoms associated with PTSD. Since there are no commercially available tVNS devices with sufficient configurability for research development for clinical deployment, our goal is to use this Phase I grant to develop and test a prototype research stimulator that supports both clinic and home use. The Phoenix® Laboratory will allow researchers to control stimulation waveform parameters, including frequency, pulse-width, duty cycle, and stimulation intensity. These features are important for dosing trials and mechanistic work to optimize neurophysiological effects of this technology and successfully translate promising basic science work to clinical application. In addition, the Phoenix Laboratory’s ability to monitor biosignals and be paired with additional wearables will allow for a higher level of data collection and analysis.”

Blythe Karow, President & CEO, said, “This is our first SBIR success, and it represents a welcome recognition of the commercial possibilities of our technology. We are excited to help the world of tVNS research move forward with this affordable and customizable device.”

While the Notice is not the official Notice of Grant Award, we expect to receive the funds (over $250,000) in early 2021.

About Evren Technologies

Evren Technologies is a development stage bioelectronic medicine company at the forefront of two of the most rapidly-growing spaces in the medical device industry: Vagal Nerve Stimulation (VNS), and wearable tech. We are bringing cutting-edge VNS technology to a user-friendly and intelligent hardware and software platform that is easy to use and personalized. Our initial product - the Phoenix® - delivers transcutaneous auricular vagal nerve stimulation in a discreet earbud design for the treatment of Post-Traumatic Stress Disorder (PTSD).


M. Blythe Karow

President and CEO

Evren Technologies, Inc.

352.533.3381 x702

200 views0 comments


bottom of page